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Abstract 
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome effecting more 
than 3 million people in the United States alone. HFpEF patients have a 5-year survival rate of 
less than 50% with no change in prognosis over the last 30 years. The lack of clinical treatments 
point to an urgent need for mechanistic studies of HFpEF pathogenesis. The cardiac remodeling 
and dysfunction in HFpEF is driven by comorbidities such as obesity, diabetes, arterial 
hypertension and endothelial dysfunction which lead to systemic inflammation. Here we report 
that, in mice, simultaneous metabolic and hypertensive stress, through the combination of high 
fat diet (HFD) and constitutive nitric oxide (NO) synthase inhibition by administration of N[w]-
nitro-l-arginine methyl ester (L-NAME) recapitulates systemic and cardiovascular alterations 
of human HFpEF. The heart failure phenotype was only observed under combined treatment 
with HFD and L-NAME and was associated with molecular changes within the 
cardiomyocytes. Specifically, the spliced form of X-box binding protein 1 (Xbp1s), a 
downstream effector of the unfolded protein response (UPR), exhibited a significant reduction 
in the HFpEF model hearts and cardiomyocytes. This decrease in Xbp1s was also observed in 
human HFpEF hearts. Reduction in Xbp1s was caused by increased inducible NO synthase 
(iNOS) activity and S-nitrosylation of IRE1α, which ultimately led to a defect in XBP1 splicing 
activity. Importantly, cardiomyocyte-specific inducible overexpression of Xbp1s partially 
ameliorated diastolic dysfunction, exercise intolerance and pulmonary congestion in HFpEF 
mice. We have developed a novel preclinical model of HFpEF, unveiling iNOS-driven 
dysregulation of Xbp1s as a crucial mechanism of cardiomyocyte dysfunction. These results 
demonstrate the essential role of protein homeostasis dysregulation in HFpEF cardiomyocytes 
and suggest that inhibiting iNOS activity may be a viable therapeutic strategy in this condition.  
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Main text  
HFpEF is a burgeoning public health problem, representing approximately 50% of HF 
hospital admissions1. The complex clinical phenotype that characterizes this syndrome stems 
from the presence of multiple comorbidities, such as obesity, hypertension, diabetes mellitus, 
and endothelial dysfunction2. Recent evidence suggests that systemic inflammation, oxidative 
stress and imbalance in NO levels are crucial for the development of clinical HFpEF3. The 
absence of truly informative preclinical models of HFpEF has led to the lack of knowledge of 
the basic pathophysiological mechanisms of this syndrome and has obviated the emergence of 
effective therapies2,4,5. 
The prevalence of the dual comorbidities of obesity and hypertension in HFpEF patients led 
us to develop our “two-hit” hypothesis. We postulated that the combination of metabolic stress 
and hypertensive stress in the animals may create the conditions in which the pathogenesis and 
clinical outcomes of human HFpEF could be recapitulated.  C57BL/6 wild-type mice were 
broken into four groups and fed with 1) high-fat diet (HFD; 60% fat from lard); 2) N[w]-nitro-l-
arginine methyl ester (L-NAME; 0.5 g/L in drinking water), an inhibitor of nitric oxide (NO) 
constitutive synthases; 3) a combination of both treatments (HFD+L-NAME) or 4) standard 
(CHOW) diet for 5/15 weeks (Fig. 1a). We chose to treat mice with L-NAME, which is widely 
used to induce experimental hypertension in laboratory animals6,7, because multiple lines of 
evidence suggest that NO dysregulation plays an important role in the pathophysiology of 
human HFpEF3,8,9. Endothelial dysfunction-induced hypertension, together with the multiple 
features of metabolic syndrome induced by HFD, represent our hypothesized “two-hit” 
mechanism underlying the natural history of HFpEF.  
Mice within all four groups were treated for 5 and 15 weeks and as expected, mice in the 
HFD groups showed an increase in body weight (BW) compared to mice fed a regular CHOW 
diet (Extended data fig 1a). No effect on BW was observed after administration of L-NAME 
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in both CHOW and HFD mice (L-NAME and HFD+L-NAME) (Extended Data Fig.1a). To 
evaluate glucose tolerance, intraperitoneal glucose tolerance tests (ipGTT) was performed. 
Consistently, both HFD and HFD+L-NAME mice exhibit glucose intolerance as evidenced by 
the persistence of high blood glucose levels compared to CHOW and L-NAME groups 
(Extended Data Fig.1b-e). As expected, L-NAME-treated mice, in both the CHOW or HFD 
regimen, exhibit a significant increase in systolic and diastolic blood pressure (SBP and DBP, 
respectively) that stabilized within 4-5 weeks and did not further increase in the 15-week time 
period (Extended Data Fig.1f,g). Thus we established a condition whereby cardiac function 
could be assessed under metabolic dysfunction and hypertensive stress, individually and in 
combination.  
Normal left ventricular (LV) EF and evidence of diastolic LV dysfunction represent two 
hallmarks of clinical HFpEF. To explore cardiac function in the different cohorts of mice, we 
evaluated both systolic and diastolic LV performance by non-invasive echocardiography. 
Cardiac function was assessed after both 5 weeks and 15 weeks of treatment (Fig. 1a). Systolic 
function as measured by EF% was normal after 15 week-treatment, in all the groups (Fig. 1b,c 
and Extended Data Table 1) as well as at 5-week time point (Extended Data Fig. 2a  and 
Extended Data Table 1).  
While human HFpEF patients have conserved EF%, many demonstrate impaired systolic 
function by measurements of longitudinal strain (LS) that correlates with diminished 
outcomes10. Interestingly, a more in deep evaluation of systolic function by speckle-tracking 
echocardiography reveals significant alterations of LV global LS (GLS) only in HFD+L-
NAME mice at both time points evaluated (Fig.1d and Extended Data Fig. 2b) demonstrating 
impaired systolic function despite preserved EF in these cohorts of mice as well. 
However, differential degrees of diastolic dysfunction were found in mice treated with HFD 
or L-NAME alone, with HFD-treated mice for 15 weeks showing a decrease in the early (E) 
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wave and increased atrial (A) wave of mitral pulse doppler (E/A) indicative of impaired 
relaxation found in early stage of diastolic dysfunction (Fig.1e,f) which was not yet detectable 
in the 5-week cohort (Extended Data Fig. 2c). In contrast, mice with the L-NAME treatment 
alone exhibit a restrictive pattern of diastolic dysfunction that is exacerbated by the HFD 
treatment at both time points (Fig.1e,f and Extended Data Fig. 2c). Indeed, the combinatory 
diet treated animals (HFD + L-NAME) display signs of significantly increased LV filling 
pressure as evidenced by increased E/A (Fig.1e,f and Extended Data Fig. 2c) as well as the 
increased ratio between E’ wave and the E’ wave on mitral tissue doppler (E/E’; Fig.1e,g and 
Extended Data Fig. 2d). Importantly, the highest degree of diastolic dysfunction in 15-week-
treated HFD+L-NAME mice was also confirmed by invasive hemodynamics data using 
pressure-volume (PV) loop analysis (Extended Data Table 1). These data indicate that a 
combination of HFD and L-NAME treatment can act in concert to produce a condition of 
diastolic dysfunction with preserved ejection fraction significantly worse than either treatment 
alone.  
A key component to a successful model of HFpEF is evidence of HF. One marker of HF is 
reduced exercise tolerance, which correlates with symptoms in clinical studies11. To investigate 
the tolerance to physical exercise in our model of HFpEF, we subjected mice from different 
groups to a treadmill exhaustion test. As expected, weight impacted exercise performance of 
HFD-treated mice at both 15-week and 5-week time points (Fig. 1h and Extended Data Fig. 
2e). However, after 15 weeks of the combinatory treatment, HFD+L-NAME mice displayed a 
significant reduction in running distance compared to all groups including those mice fed only 
a HFD (Fig.1h). Furthermore, while hearts from all three treated groups exhibit cardiac 
hypertrophy, as shown by the increase in heart weight/tibia length ratio (HW/TL) (Fig. 1i and 
Extended Data Fig. 2f), this response is greatest in the HFD+L-NAME mice after 15 weeks 
of treatment (Fig.1i) More importantly, only the HFD+L-NAME mice exhibit signs of HF, as 
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shown by robust increase in the ratio of wet:dry lung weight (LW) (Fig.1j and Extended Data 
Fig. 2g), a marker of pulmonary congestion and a preclinical surrogate for HF. Cardiac structure 
alterations were also found. Indeed, histological analysis of 5 week-treated hearts, revealed 
increased heart mass, cardiomyocyte hypertrophy and increased fibrosis in mice treated with 
L-NAME or the combination of HFD+L-NAME (Extended Data Fig. 3a-c). Collectively these 
results demonstrated that the HFD+L-NAME mice recapitulate the systemic and cardiac 
alterations of HFpEF patients including diastolic dysfunction and HF. 
Microvascular alterations and increased vascular stiffness are also recognized in clinical 
HFpEF12. Mice subjected to as little as 5 week-chronic L-NAME treatment exhibit high aortic 
stiffness as shown by a significant increase in pulse wave velocity (PWV) across the arterial 
system (Extended Data Fig.4a). Subsequently, in order to explore the presence of coronary 
dysfunction in mice subjected to the different treatments, we measured coronary flow reserve 
(CFR) using short term exposure of high isoflurane (Iso) to induce hyperemic coronary blood 
flow. Interestingly in both L-NAME and HFD+L-NAME mice, the coronary vasodilatatory 
response induced by Iso was significantly blunted, with parallel reduction of CFR (Extended 
Data Fig. 4b,c). Finally, myocardial capillary density was also significantly reduced in L-
NAME-treated mice (Extended Data Fig. 4d,e). Although the vascular alterations occurred in 
all L-NAME treated groups, the addition of increased diastolic dysfunction and the HF 
symptoms in the HFD + L-NAME group further supports this treatment as a model of HFpEF. 
Although HFpEF is known to be a systemic disease involving complex pathophysiological 
interactions between different cell types, tissues and organs, alterations in cardiomyocyte 
contraction and relaxation represent to date a recognized common background13,14. Adult 
mouse ventricular myocytes (AMVMs) were isolated from hearts of different experimental 
groups after 5 weeks of dietary regimen in order to investigate the presence of cardiomyocyte 
dysfunction. AMVMs were externally paced and rates of sarcomeres shortening and 
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relengthening were measured after electrical stimulation. Interestingly, although no differences 
were observed in baseline sarcomeric length (Extended Data Fig.5a) and in time to peak 
velocity (Extended Data Fig.5b) among the four groups, AMVMs isolated from HFD+L-
NAME mice exhibit a significant reduction in contraction and impaired relaxation (Extended 
Data Fig.5c-f) compared to AMVMs isolated from other experimental groups. These data 
confirmed that the alterations in cardiac mechanics observed in our HFpEF model can be 
recapitulated in isolated AMVMs 
Our evidence thus far suggested that, functionally and structurally, HFD+L-NAME 
treatment results in distinct functional and physical changes in the heart compared to either 
treatment alone, mirrored many of the clinical symptoms of human HFpEF. We next looked for 
molecular differences in cardiomyocytes between these groups that might provide insight to the 
pathological progression of this syndrome.  The unfolded protein response (UPR) represents a 
crucial adaptive response system able to mitigates stress under many conditions that interfere 
with protein quality control15. Recently, accumulation of misfolded proteins has been 
recognized in clinical HFpEF, posing the attention on protein handling dysregulation also in 
this syndrome16. Regulators of protein quality control in HFpEF are currently unknown. 
Although the activation of all three branches of UPR – inositol-requiring protein 1α(IRE1α), 
protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6) 
transducers – happens in many diseases, disproportional activation of single branches it has also 
been reported17,18. In this context, IRE1α plays an important role in maintaining endoplasmic 
reticulum (ER) function through initiating unconventional splicing of the mRNA encoding X-
box–binding protein 1 (Xbp1) to generate spliced X-box binding protein 1 (Xbp1s), a powerful 
transcription factor involved in many fundamental cellular functions15. We recently discovered 
the cardioprotective role of Xbp1s overexpression during cardiac ischemia/reperfusion injury19 
and we hypothesized that activation of the UPR can trigger beneficial effects on cardiac 
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remodeling also during the development of HFpEF. Therefore, we first analyzed the mRNA 
expression levels of the most important UPR markers in hearts of different experimental groups 
after 5 weeks of dietary regimen. As expected, we found a strong activation of UPR sensors 
and effectors in HFD and L-NAME hearts, but surprisingly a significant reduction below 
baseline in expression levels of Xbp1s, BIP, CHOP was found in HFD+L-NAME mouse hearts 
(Fig. 2a). Importantly, we confirmed Xbp1s and other markers inactivation also in AMVMs 
isolated from HFD+L-NAME mice at both mRNA and protein level (Fig. 2b,c). These findings 
show a clear molecular difference in the cardiomyocytes of HFD+L-NAME treated animals 
that correlates with the emergence of HF. 
We next turned to endomyocardial biopsies of control and failing human hearts to see if the 
molecular changes we observed also occurred. Strikingly, Xbp1s mRNA levels was also found 
downregulated in human HFpEF myocardium but not in samples from patients with HF with 
reduced ejection fraction (HFrEF) (Fig. 2f and Extended Data Table 2). These data confirm 
that the Xbp1s downregulation observed in our animal model also occurs in the context of 
human HFpEF. 
Our data showed that the down-regulation of Xbp1s correlated with the development of 
HFpEF in our animal model. To examine more directly whether a decrease in this transcription 
factor could be complicit in the pathophysiology of HFpEF, we took advantage of a 
cardiomyocyte-specific Tet-off Xbp1s overexpression transgenic mouse line (TG)19. Xbp1s is 
expressed only in cardiomyocytes and suppressed in the presence of doxycycline (Doxy). 
Littermate control (CTR) and Xbp1s transgenic animals (TG) were treated with either normal 
CHOW or HFD+L-NAME with the presence of Doxy in the drinking water (Fig. 3a).  Serial 
echoes, both before treatment and 5 weeks after treatment, were done to confirm the diastolic 
dysfunction was induced in the HFD+L-NAME groups with conserved LVEF%(Fig. 3b-d). 
Once the phenotype was established Xbp1s expression was induced by removing Doxy for 2 
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weeks (Fig. 3a and Extended Data Fig. 7) and mice were subjected to further functional and 
molecular analyses. Remarkably, two weeks of Xbp1s expression was sufficient to drive a 
significant amelioration of the diastolic dysfunction as shown by the reduction of E/A and E/E’ 
ratios compared to CTR (Fig. 3c, d) without impacting on LVEF% (Fig. 3b). This increase in 
diastolic performance was associated with a significant increase in exercise tolerance in these 
animals (Fig. 3e) as well as a decrease in pulmonary edema (Fig. 3f) and in the mRNA 
expression of HF-related genes, atrial natriuretic peptide (nppa) and brain natriuretic peptide 
(nppb) (Fig. 3g). Interestingly, no significant reduction in cardiac hypertrophy was observed 
after 2 weeks of Xbp1s expression (Fig. 3h). Taken together, these data demonstrate that 
overexpression of Xbp1s in cardiomyocytes is sufficient to ameliorate the diastolic dysfunction 
and signs of HF observed in HFpEF mice and suggest a model by which decreased Xbp1s levels 
are a driving force in the development of HFpEF.  
As stated before, endothelial dysfunction and dysregulation of NO synthesis represent 
important components of HFpEF pathophysiology. In fact, L-NAME, which we use as a driver 
of hypertension, is a potent inhibitor of endothelial NOS (eNOS). However, at the same time 
L-NAME has also been suggested to be an activator of inducible nitric oxide synthase (iNOS) 
in cardiovascular system20. Similarly, iNOS has been shown to be upregulated in rodent hearts 
under HFD conditions21. We therefore examined whether iNOS levels were altered in our model 
system. As has been reported, a significant increase of iNOS expression level, was found in the 
hearts of both HFD and L-NAME treated mice after 5 weeks of dietary regimen, whereas no 
differences were observed in eNOS expression level (Fig.4a). Strikingly, the combination of 
HFD + L-NAME resulted in a dramatic increase in iNOS levels in the hearts over either single 
treatment (Fig.4a). Isolation of AMVMs from all four groups of these animals confirmed that 
the changes in iNOS levels were mirrored at the cardiomyocyte level (Fig.4b). High levels of 
NO generate S-nitrosylation of protein’s cysteine residues, and can regulate their function22,23. 
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Accordingly, we observed a significant increase of total protein nitrosylation in hearts of HFD 
+ L-NAME mice (Fig.4c,d). 
The observation that levels of iNOS expression was increased in cardiomyocytes from HFD 
+ L-NAME treated mice raised the possibility of a connection between iNOS levels and the 
decrease in Xbp1s. Prior studies have shown that in the livers of extremely obese mice, iNOS-
dependent S-nitrosylation of IRE1α can inhibit its function, resulting in reduction in Xbp1 
splicing21. In order to examine whether a similar effect can occur in myocytes, recombinant 
adenovirus driving iNOS expression (AdiNOS) was used in neonatal rat ventricular myocytes 
(NRVMs). Increasing concentrations of AdiNOS resulted, in a robust increase in iNOS 
expression whereas control infection with a β-galactosidase adenovirus (AdLacZ) had no effect 
on iNOS expression (Extended Data Fig. 6a,b). iNOS overexpression significantly increases 
NO production in NRVMs culture media (Extended Data Fig. 6c) without significantly impact 
on cardiomyocyte viability (Extended Data Fig. 6d). Importantly, transduction with AdiNOS 
resulted in a bi-phasic response of Xbp1s mRNA expression levels, with an initial rise and 
subsequent significant fall below the basal levels (Extended Data Fig. 6e). Interestingly this 
pattern mirrors the correlation between iNOS levels and Xbp1s in the hearts of the four 
treatment groups. In the HFD+L-NAME hearts, evidence of increased S-nitrosylation of IRE1α 
(Fig. 4e,f) and decreased autophosphorylation of IRE1α (Fig. 2c) is observed in support of a 
mechanism whereby Xbp1s reduction in preclinical HFpEF is attributed to S-nitrosylation of 
IRE1α.  
HFpEF is a lethal disease for which no current therapies have consistently show beneficial 
effects. Absence of effective etiological therapies in HFpEF is related to the relatively poor 
knowledge of its fundamental pathophysiological mechanisms, many of them remain 
hypothetical due to the absence of robust preclinical data. In fact, to date, no reliably predictive, 
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preclinical models of HFpEF exist as many focus only on single components of the human 
disease but do not recapitulate its complexity5,24. For example, in pressure overload-induced 
hypertrophy models such as the one realized through transverse aortic constriction (TAC), the 
presence of HFpEF represents only a transient stage of the natural history of this model, which 
inexorably progress to HFrEF over time. Given the limitations of current pre-clinical models of 
HFpEF, we developed a novel murine model of HFpEF in which no apparent reduction in EF 
has been recognized over a extended period of observation. Indeed, within 5 weeks of treatment 
the manifestation of the HFpEF phenotype becomes apparent with underlying the fact that the 
observed cardiovascular phenotype in those mice represents an established disease state.  
Moving forward, we extended the knowledge of basic pathophysiological mechanisms of 
this syndrome. Current thinking identifies inflammation as a major cause of microvascular 
dysfunction and reduced NO bioavailability in clinical HFpEF. However, although 
epidemiologic studies have shown increased levels of circulating cytokines25-27, so far, no 
mechanistic studies have provided robust evidences of inflammatory involvement in HFpEF 
pathophysiology. Here we focused on metabolic inflammation (meta-inflammation) and on its 
master mediator, iNOS, demonstrating the important role of inflammatory-dependent 
alterations in this syndrome.  
Current treatments of HFpEF that have been focused on increasing NO bioavailability have 
reported neutral24,28,29 or negative results30,31. In our preclinical model of HFpEF we have shown 
that excessive production of NO, induced by the pro-inflammatory activation of iNOS, affects 
protein quality control in cardiomyocytes leading to contractile dysfunction. Our results, 
indeed, give a biological explanation for the failure of NO-inducing approaches as therapeutic 
options. Therefore, turning the attention to strategies focusing on reducing iNOS activation, as 
has been done in other disease32, could represents a valid approach also in HFpEF.  
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Working from the clinical realities of HFpEF, including multi-organ co-morbidities, we have 
developed the first murine model of model of HFpEF that recapitulates most of the myriad, 
features of the clinical syndrome and uncovered a the iNOS-dependent regulation of Xbp1s as 
a novel pathophysiological mechanism of this syndrome. 
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Methods 
Experimental animals 
All experiments involving animals were conform to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication 8th 
edition, update 2011), and were approved by the Institutional Animal Care and Use Committee 
of the University of Texas Southwestern Medical Center. Adult (8-12-week-old), male 
C57BL/6J mice were used for wild-type (WT) studies. TRE-Xbp1s mouse were crossed with 
the  MHC-tTA mouse model to generate mice with cardiomyocyte-specific deletion of Xbp1s 
(TG) as previously described19. Mice were maintained on a 12-hour light/dark cycle from 6 AM 
to 6 PM had unrestricted access to food (#2916, Teklad for CHOW groups and D12492, 
Research Diet Inc. for the HFD groups) and water. N[w]-nitro-l-arginine methyl ester (L-NAME; 
0.5 g/L, Sigma Adrich) was supplied in drinking water for the indicated periods of time, after 
adjusting the pH to 7.4.  
 
Conventional echocardiography and Doppler imaging 
Transthoracic echocardiography was performed using a VisualSonics Vevo 2100 system 
equipped with MS400 transducer (Visual Sonics Inc.). Left ventricular (LV) EF and other 
indexes of systolic function were obtained from short axis M-mode scans at mid ventricular 
level, as indicated by the presence of papillary muscles, in conscious, gently restrained mice. 
Apical 4-chamber view was used to obtain diastolic function measurements using pulse wave 
and tissue Doppler at the level of mitral valve in anesthetized mice. Anesthesia was induced by 
5% isoflurane and confirmed by lack of response to firm pressure on one of the hind paws; 
during echocardiograms acquisition, under body temperature controlled conditions, isofluorane 
was reduced to 1.0-1.5% and adjusted to maintain heart rate in the range of 415-460 beats per 
minute monitoring ECG. Parameters include: heart rate (HR), left ventricular end-diastolic 
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diameter (LVID,d), left ventricular end-systolic diameter (LVID,s), end-diastolic  
interventricular septal wall thickness (IVS,d), left ventricular end-diastolic posterior wall 
(LVPW,d), left ventricular fractional shortening (LVFS), left ventricular ejection fraction 
(LVEF); peak Doppler of blood inflow velocity across mitral during early diastole (E), peak 
Doppler of blood inflow velocity across mitral during late diastole (A), isovolumic relaxation 
time (IVRT), peak tissue Doppler of myocardial relaxation velocity at mitral valve annulus 
during early diastole (E’), early filling deceleration time (DT). At the end of the procedures all 
mice recovered from anesthesia without difficulties. All parameters were measured at least 3 
times and the averages were presented.  
 
Speckle tracking echocardiography and strain analysis 
B-mode traces acquired from the parasternal long-axis view were used to calculate global 
strain for longitudinal dimensions with the VevoStrain software (Visual Sonics Inc.) using a 
speckle-tracking algorithm. Velocity and displacement were also calculated in both the long- 
and short-axes. Values generated by strain analysis in longitudinal dimension were negative 
which illustrates fiber shortening. B-mode images were selected based on the quality of them 
(high frame rates) and on the ability to visualize both the endocardial and epicardial LV wall 
borders. Borders of the endocardium and epicardium were traced and semi-automated strain 
analysis was performed. Average peak global strain values were obtained from six independent 
anatomical segments of the LV.  
 
Coronary flow reserve  
Coronary flow velocity was measured in cine traces of left proximal coronary artery using 
pulsed-wave Doppler-mode at baseline, and under hyperemic conditions induced by inhalation 
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of 1.5% and 3.0% isoflurane, respectively. CFR was expressed as the ratio between peak blood 
flow velocity during hyperemia and peak blood flow velocity at baseline. 
 
Noninvasive blood pressure measurements  
Systolic blood pressure was noninvasively measured in conscious mice by tail-cuff method 
using the CODA instrument (Kent Scientific). Animals were placed in a holder on a 
temperature-controlled platform (kept at 37 °C), and recordings were performed in steady-state 
conditions. Blood pressure values were averaged from at least three consecutive measurements.  
 
Pulse wave velocity  
Pulse wave velocity (PWV) was noninvasively measured over the entire aorta. Pulsed 
Doppler images were obtained at the ascending aorta (just cranial to the aortic valve) and the 
abdominal aorta (just cranial to the iliac bifurcation). Subsequently the distance between both 
locations was approximated by an external body tape measurement. PWV was calculated as the 
ratio of  X and  T (PWV= X/ T), where  X is the distance between the due anatomical 
location where the Doppler signals were recorded and  T is the foot-to-foot transit time 
between averaged waveforms at both locations. 
 
Pressure-volume analysis 
Apical approach was used to obtain PV measurements from anesthetized mice using a mouse 
PV catheter (Milllar instruments). Inferior vena cava was located and occluded during a pause 
in ventilation to acquire load-independent indexes. Data were analyzed using PV Lab Chart 
software. 
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Exercise exhaustion test 
After 3 days of acclimatization period on treadmill, exhaustion test was performed in all 
groups of mice. Animals ran on the treadmill tilted 20° uphill starting at a warm-up speed of 5 
m/min for 4 min after which speed was increased to 14m/min for 2 min. Every subsequent 2 
min, the speed was increased by 2 m/min until mice were exhausted. Exhaustion was defined 
as the inability of the animal to return to running within 10 seconds after direct contact with an 
electric-stimulus grid. Running time was measured and running distance calculated.  
 
Intraperitoneal glucose tolerance test  
Intraperitoneal glucose tolerance test (ipGTT) was performed by injection of glucose (2 g/kg 
in saline) after 6-hour fasting. Tail blood glucose levels [mg/dl] were measured with glucometer 
before (0 min) and at 15, 30, 45, 60 and 120 min after injection. 
 
Histology 
Hearts were fixed in 4% paraformaldehyde (PFA) overnight and paraffin cross-section 
(5 m) were stained with hematoxylin and eosin, Masson’s trichrome. Wheat germ agglutinin 
(WGA) staining and lectin staining were used to measure cardiomyocyte cross-sectional area 
and to quantify capillary density respectively. After deparaffinization and antigen retrieval with 
hot citrate buffer, cardiac slides were incubated with WGA conjugated to Alexa Fluor 488 (50 
mg/ml) for one hour at room temperature or with bitoin conjugate lectin from Griffonia 
simplicifolia overnight at 4°C. Cardiomyocyte size and capillary numbers were quantified using 
Image J software.  
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Cardiomyocyte isolation 
AMVMs were isolated from littermates of different experimental groups. Briefly, hearts 
were isolated and immediately retrograde perfused with perfusion buffer for 1 min and the 
switched to a buffer containing liberase-TM (0.025 mg/mL, Roche) and trypsin (0.025%) for 
14 min. The left ventricle was dissected and minced in perfusion media supplemented with 10% 
dialyzed FBS. After filtration, AMVMs were let to sediment by gravity and non-
cardiomyocytes were discarded. Calcium reintroduction was done stepwise from 0-1.8 mM in 
6 steps. NRVMs were isolated from 1-2 day old Sprague-Dawley rat pups as previously 
described. Cell preparations contained greater than 95% cardiomyocytes. 
 
Sarcomere length measurements in paced cardiomyocytes  
Sarcomere shortening and relaxation was measured in freshly isolated AMVMs using the 
integrated IonOptix contractility/photometry system. Briefly, AMVMs were electrically 
stimulated at 0.5 Hz using a field stimulator. Parameters measured include basal sarcomeric 
length, delta sarcomeric length after contraction, maximum departure/return velocities and time 
to peak. All measurements were performed at room temperature from 3 different heart 
preparations per group. 
 
Adenovirus production, purification and infection  
Mouse iNOS CDNA was obtained from Addgene (#19295) was subcloned into an 
adenovirus expression vector using Adeno-X™ Adenoviral System 3 (CMV promoter and 
Zsgreen1 reporter, Takara) following the manufacturer instructions.  Adenoviruses were 
harvested from culture supernatant and cell lysates, the viral titer was determined, and virus 
aliquots were store at -80°C. NRVMs were infected with increasing multiplicity of infection 
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(MOI) of virus and cells were harvested 24-hour post-infection. AdLacz construct contained in 
the kit was used a control at the same MOI. 
 
RNA Isolation and qPCR 
Total RNA was isolated from hearts, AMVMs or NRVMs using TRIzol reagent or Quick-
RNA™ MicroPrep kit (Zymo Reaserch). A total of 100-500 ng RNA was used for reverse 
transcription using iScript reagent (Bio-Rad). qPCR reactions were performed in triplicate with 
SYBR master mix (Bio-Rad). The 2- CT relative quantification method, using 18S for 
normalization, was used to estimate the amount of target mRNA in samples and fold ratios were 
calculated relative to mRNA expressions levels from control animals. The following PCR 
primers sequences were used (forward, reverse): Xbp1s-mouse/rat 
(GGTCTGCTGAGTCCGCAGCAGG, GAAAGGGAGGCTGGTAAGGAAC); BIP-mouse 
(CATGGTTCTCACTAAAATGAAAGG, GCTGGTACAGTAACAACTG); ATF6-mouse 
(AGAAAGCCCGCATTCTCCAG, ACTCCCAGAATTCCTACTGATGC); ATF4-mouse 
(ATGGCCGGCTATGGATGAT, CGAAGTCAAACTCTTTCAGATCCATT); CHOP-mouse 
(CTGCCTTTCACCTTGGAGAC, CGTTTCCTGGGGATGAGATA); NOS2-mouse 
(GTTCTCAGCCCAACAATACAAGA, GTGGACGGGTCGATGTCAC); NOS3-mouse 
(TCAGCCATCACAGTGTTCCC, ATAGCCCGCATAGCGTATCAG); NPPA-mouse 
(CTGGGACCCCTCCGATAGAT, TTCGGTACCGGAAGCTGTTG); NPPB-mouse 
(TTTGGGCTGTAACGCACTGAA, TGTGGCAAGTTTGTGCTCCA); 18S-mouse/rat 
(AAACGGCTACCACATCCAAG, CCTCCAATGGATCCTCGTTA); Xbp1s-human 
(CTGAGTCCGCAGCAGGTG, GTCCAGAATGCCCAACAGGA); GAPDH-human 
(TCAACGACCACTTTGTCAAGCTCA, GCTGGTGGTCCAGGGGTCTTACT).  
 
 
 20 
Immunoblot analysis 
Protein extracts from frozen mouse hearts, AMVMs and NRVMs were obtained by lysis in 
ice-cold modified RIPA buffer (150 mM NaCl, 50 mM Tris HCL pH 7.4, 1% Triton-X 100, 
0.5% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 2 mM EDTA) containing protease and 
phosphatase inhibitors. Protein were separated under reducing conditions on SDS-
polyacrylamide 4%-20% gradient gels (Bio-Rad) and transferred to nitrocellulose membranes. 
Proteins were detected with the following primary antibodies: anti-pIRE1α [Ser724] (NB100-
2323, Novus Biological); anti-GRP94 (#2104, Cell Signaling); anti-iNOS (#13120, Cell 
Signaling); anti-GAPDH (10R-G109a, Fitzgerald). Odyssey scanner (LI-COR) was used as a 
detection system. 
 
Measurement of nitrite and nitrate  
The amount of nitrite (NO2-) and nitrate (NO3-), the breakdown products of NO, were 
measured in tissue or cell media with the Nitrate/Nitrite colorimetric assay kit (Cayman 
Chemicals) according to the manufacturer’s instructions.  
 
Lactate dehydrogenase (LDH) assay 
To evaluate cell survival, LDH assay was performed using the CytoTox96 cytotoxicity kit 
(Promega) according to the manufacturer’s instructions. LDH release was calculated as follow: 
(medium LDH)/(medium LDH + intracellular LDH). 
 
Determination of S-nitrosylation 
Hearts were excised, snap-frozen in liquid nitrogen and stored at -80ºC until 
homogenization. Tissue was homogenized in immunoprecipitation (IP) buffer (25 mM sodium 
phosphate pH 7.2, 150 mM, NaCl, 10 % Glycerol, 1 mM EDTA, 1% triton, 
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protease/phosphatase Inhibitors) supplemented with 0.1 mM neocuproine, using an electric 
homogenizer on ice. Lysates were spun at 10,000xg and supernatants were used for protein 
determination using BCA method. Free cysteines were blocked at room temperature in HENS 
buffer (100 mM HEPES (pH 7.0), 1 mM EDTA, 0.1 mM neocuproine, and 2% SDS) using N-
Ethylmaleimide (ratio 5 ug NEM per 1 ug protein). Proteins were acetone-precipitated, and 
pellet washed using acetone:water (4:1). Protein pellet was resuspended in HENS buffer pH8.0 
and labeled using 40 mM ascorbic acid and TMT 0.2 mM. Negative control without ascorbic 
acid and positive control with GSNO 1 mM were included for labeling. Immunoprecipitation 
was carried out using 500 ug labeled protein and 5 uL IRE1α (Cell Signaling, #3294) and 25 
uL Dynabeads Protein G in IP buffer overnight at 4C. Beads were magnetically separated and 
washed 5 times with IP buffer and then eluted using a 2x Laemmli buffer. 
 
Human myocardial tissue 
Human myocardial tissue samples collection was performed under protocols approved by 
Institutional Review Boards at the Johns Hopkins University (Maryland, USA) and consent for 
biopsy procedures or use of explanted tissues prospectively obtained in all cases. Explant 
dilated failing human hearts were procured at the time of orthotopic heart transplantation. 
Samples were full-thickness biopsies obtained from the free wall of the left ventricle. HFpEF 
patients were referred for cardiac catheterization and right ventricular endomyocardial biopsy 
because of clinical suspicion of infiltrative cardiomyopathy. Control samples for these studies 
were obtained from explanted unused donor hearts. 
 
Statistical analysis 
Data is presented as bar graphs or box-and-whisker plots. Bar graph show mean, and the 
error bars represent S.E.M. Box-and-whisker plots show median, the first and third quartiles, 
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and minimum and maximum values. All data met assumptions of the statistical test and different 
groups had similar variance. Differences were analyzed by unpaired Student t test for 
experiments with 2 groups, or one-way analysis of variance (ANOVA) plus Sidak’s post hoc 
test for multiple comparisons or two-way ANOVA plus Tukey–Kramer’s post hoc test as 
appropriate in experiments including ≥3 groups. A minimum value of p<0.05 was considered 
statistically significant. All experiments were done with at least three biological replicates. All 
statistical analyses were conducted using GraphPad Prism software 7.0. Categorical variables 
in the Extended Data Table 2 were compared using chi-square test using SPSS Statistics 
version 19 (SPSS Inc., Chicago, IL). No statistical analysis was used to predetermine sample 
size which was chose based on our previous experience. No data were excluded from the 
analyses. No randomization was used to allocate animals to experimental groups, and 
investigators were not blinded to group allocation during experiments except for the data 
included in Extended Data Figure 5.  
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Figure legends 
 
Figure 1 
15 weeks of combination of HFD and L-NAME treatment in mice recapitulates the 
systemic and cardiovascular alterations of clinical HFpEF. 
a, Experimental design. C57BL/6 mice were exposed to the different dietary regimens (blu 
filled triangle) and followed up to 15 weeks. Echocardiography (Echo), blood pressure 
measurements (BP), intraperitoneal glucose tolerance test (ipGTT), exercise exhaustion test, 
pulse wave velocity measurements (PWV), coronary flow reserve measurements (CFR), adult 
mouse ventricular myocytes (AMVMs) isolation and tissue harvesting were performed at the 
indicated time points (empty triangles). b, Representative left ventricular (LV) M-Mode 
echocardiographic tracings from different experimental groups. c, LV % ejection fraction of 
different experimental mice (n=15/group). d, Global longitudinal strain (GLS) assessment in 
mouse hearts from different experimental groups (n=8/group). e, Representative pulse wave 
Doppler (top) and tissue Doppler (bottom) tracings from different experimental groups. f, E/A 
ratio of different experimental mice (n=15/group). g, E/E’ ratio of different experimental mice 
(n=15/group). h, Running distance during exercise exhaustion test in different experimental 
group of mice (n=8/group). i, Heart weight to tibia length ratio (HW/TL) in different 
experimental group of mice (n=15/group). j, Ratio between lung weight (LW) immediately 
after mouse euthanasia (wet) and after 48h at 65°C (dry) in different experimental group of 
mice (n=15/group). Box-and-whisker plots show the median, the first and third quartiles, and 
the minimum and maximum values. Bar graphs show mean ± s.e.m. In d *p<0.05, 1-way 
ANOVA plus Sidak’s multiple comparisons test. In f,g,h,i,j **p<0.001 and ****p<0.00001, 1-
way ANOVA plus Sidak’s multiple comparisons test. 
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Figure 2 
Robust inactivation of Xbp1s in hearts and cardiomyocytes of HFD + L-NAME mice after 
five weeks of diet and in human hearts HFpEF samples. 
a, mRNA levels of unfolded protein response (UPR) markers in hearts of different experimental 
groups (n=5/group). b, mRNA levels of UPR markers in AMVMs of CHOW and HFD + L-
NAME mice (n=5/group). c, Representative immunoblot images of pIRE1α, GRP94 and 
GAPDH proteins in AMVMs of CHOW and HFD + L-NAME mice. Arrow indicates the 
regulated band. Thapsigargin (Thaps) treatment was used in CHOW AMVMs as a positive 
control to induce UPR. d, Bar graphs showing the ratio between pIRE1α and GAPDH protein 
bands intensity quantification (n=5/group). e, Bar graphs showing the ratio between GRP94 
and GAPDH protein bands intensity quantification (n=5/group). f, mRNA levels of Xbp1s in 
right ventricle biopsies from HFpEF and HFrEF subjects (n=12-15/group). In a,f **p<0.001 
and ***p<0.0001, 1-way ANOVA plus Sidak’s multiple comparisons test. In b,d,e **p<0.001, 
unpaired Student t test. Data represent mean ± s.e.m for a,b,d,e and box-and-whisker plots show 
the median, the first and third quartiles, and the minimum and maximum values for f.  
 
Figure 3 
Cardiomyocyte-specific Xbp1s overexpression ameliorates diastolic dysfunction and 
heart failure in experimental HFpEF mice. 
a, Experimental design. Control (CTR) and XP1s transgenic mice (TG) were exposed to 
CHOW or HFD+L-NAME combination of diet (green filled triangle). After five weeks, 
doxycycline (Doxy) was removed from the drinking water to induce the transgene expression 
for 2 weeks (blue empty triangle). After this time, mice were subjected to functional analysis 
and tissue harvesting (Echo, BP, exercise test, tissue harvesting – yellow empty triangle). b, 
LV % ejection fraction of different experimental mice over time (n=7/group). c, E/A ratio of 
 29 
different experimental mice over time (n=7/group). d, E/E’ ratio of different experimental mice 
over time (n=7/group). e, mRNA levels of nppa and nppb genes in LV of different experimental 
group of mice at the end of the study (n=5/group). f, Running distance during exercise 
exhaustion test in different experimental group of mice at the end of the study (n=7/group). g, 
Ratio between wet LW and dry LW in different experimental group of mice at the end of the 
study (n=7/group).  h, HW/TL in different experimental group of mice at the end of the study 
(n=7/group). Data represent mean ± s.e.m for b,c,d,e and box-and-whisker plots showing the 
median, the first and third quartiles, and the minimum and maximum values for f,g,h. 
**p<0.001 CTR vs. TG and ###p<0.0001 CHOW vs. HFD + L-NAME, 2-way ANOVA. 
 
Figure 4 
Increased iNOS levels and IRE1α protein S-nitrosylation in experimental HFpEF. 
a, mRNA levels of eNOS and iNOS in hearts of different experimental groups (n=5/group). b, 
mRNA levels of iNOS in AMVMs of CHOW and HFD + L-NAME mice (n=5/group). c, 
Representative immunoblot image of TMT and GAPDH proteins in LV of CHOW and HFD + 
L-NAME mice. d, Bar graphs showing the ratio between protein bands intensity quantification 
(n=4/group). e, Representative immunoblot images of SNO-IRE1α and IRE1α proteins in total 
nitrosylated pool of proteins from LV of CHOW and HFD + L-NAME mice. f, Bar graphs 
showing the ratio between protein bands intensity quantification (n=4/group). In a *p<0.05 and 
**p<0.01, 1-way ANOVA, in b,d,f *p<0.05, unpaired Student t test. Data represent mean ± 
s.e.m. 
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Extended Data Figure 1. Body weight, glucose tolerance test and blood pressure measurements
after 5 or 15 weeks of different treatments. a, Body weight (BW) in different experimental groups (5
weeks: n=10/group;; 15 weeks: n=15/group). b, Intraperitoneal glucose tolerance test (ipGTT) in different
experimental groups after 5 weeks of treatment (n=10/group). c, Bar graphs representing the area under the
curve of ipGTT experiment (n=10/group). d, ipGTT in different experimental groups after 15 weeks of
treatment (n=10/group). c, Bar graphs representing the area under the curve of ipGTT experiment
(n=10/group). f, Systolic blood pressure (SBP) and g, diastolic blood pressure (DBP) in different
experimental groups at different time points (5 weeks: n=10/group;; 15 weeks: n=15/group). Data are
presented as box-­and-­whisker plots showing the median, the first and third quartiles, and the minimum and
maximum values, or bar graphs showing mean±s.e.m. *p<0.01, **p<0.001 and ***p<0.0001, 1-­way ANOVA
plusSidak’smultiple comparisons testor by repeatedmeasurements 1-­wayANOVA.
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Extended Data Figure 2. Cardiac function characterization and systemic phenotype of mice after 5
weeks of different treatments. a, LV % ejection fraction of different experimental groups of mice
(n=10/group). b, Global longitudinal strain (GLS) assessment in mouse hearts from different experimental
groups (n=5/group). c, E/A ratio of different experimental mice (n=10/group). d, E/E’ ratio of different
experimental mice (n=10/group). e, Running distance during exercise exhaustion test in different
experimental group of mice (n=10/group). f, Heart weight to tibia length ratio (HW/TL) in different
experimental group of mice (n=10/group). g, Ratio between lung weight (LW) immediately after mouse
euthanasia (wet) and after 48h at 65°C (dry) in different experimental group of mice (n=10/group). Box-­and-­
whisker plots show the median, the first and third quartiles, and the minimum and maximum values. Bar
graphs showmean±s.e.m. *p<0.01 and **p<0.001,1-­wayANOVAplusSidak’smultiple comparisons test.
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Extended Data Figure 3. Cardiac hypertrophy and fibrosis in 5-­week-­treated mice. a, Representative
images of hematoxylin & eosin (H&E), wheat germ agglutinin (WGA) and Masson’s Trichrome staining (MT)
of LV of different experimental groups of mice (n=10/group). Scale bar 50 µm. b, WGA quantification of
mean cross sectional area of 80-­10 cardiomyocytes per field (n=10/group;; 4 fields/heart). f, Fibrosis area %
of MT stained cross sections (n=10/group;; 4fields/heart). Box-­and-­whisker plots show the median, the first
and third quartiles, and the minimum and maximum values. **p<0.001, 1-­way ANOVA plus Sidak’s multiple
comparisons test.
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Extended Data Figure 4. Vascular characterization of mice after 5 weeks of different treatments. a,
Pulse wave velocity (PWV) in different experimental group of mice (n=5/group). b, Representative pulse
wave Doppler tracings of coronary flow in CHOW (top panels) and HFpEF (bottom panels) under basal
condition (left panels – Iso 1.5%) and after hyperemic stimulus (right panels – Iso 3%). c, Coronary flow
reserve (CFR) quantification in different experimental group of mice (n=6/group). d, Representative images
of lectin staining of heart sections in different experimental groups. Capillaries appear brown. Scale bars: 50
μm. e, Capillary density in hearts of of different experimental groups (n=6/group). Data are presented as
box-­and-­whisker plots showing the median, the first and third quartiles, and the minimum and maximum
values. *p<0.05 and **p<0.001,1-­wayANOVAplusSidak’smultiple comparisons test.
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Extended Data Figure 5. Adult mouse ventricular cardiomyocytes contractility in mice after 5 weeks
of different treatments. a, Baseline sarcomeric length (n=5/group). b, Time to peak (n=5/group). c,
Maximum departure velocity (n=5/group). d, Maximum return velocity (n=5/group). e, Change in sarcomeric
length related to baseline (n=5/group). f, Representative tracings of cardiomyocyte contraction/relaxation
during pacing (n=5/group). Data are presented as bar graphs showing mean±s.e.m. *p<0.05 and **p<0.001,
1-­wayANOVAplusSidak’smultiple comparisons test.
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Extended Data Figure 6. iNOS overexpression reduces Xbp1s levels without affecting
cardiomyocyte viability. a, Representative images of iNOS and GAPDH immunoblots of NRVMs infected
with increasing MOI of AdlacZ and AdiNOS for 24 hours. b, iNOS mRNA level of NRVMs transduced with
increasing MOI of AdlacZ and AdiNOS for 24 hours (n=5). c, Medium Nitrite/Nitrate concentration of NRVMs
infected with increasing MOI of AdlacZ and AdiNOS for 24 hours (n=5). d, Lactate dehydrogenase (LDH)
release in NRVMs transduced with increasing MOI of AdiNOS for 24 hours (n=4). e, Xbp1s mRNA level of
NRVMs infected with increasing MOI of AdlacZ and AdiNOS for 24 hours (n=5). Data are presented as bar
graphs showing mean±s.e.m. **p<0.001, ***p<0.0001, ##p<0.001 1-­way ANOVA plus Sidak’s multiple
comparisons test.
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Extended Data Figure 7. XBP1s transgene overexpression in XBP1s TG mice. Xbp1s mRNA level in
control (CTR) and XP1s transgenic mice (TG) fed with CHOW or HFD + L-­NAME combination of diet for
seven weeks. Data are presented as bar graphs showing mean±s.e.m. **p<0.001, ####p<0.00001 1-­way
ANOVA plusSidak’smultiple comparisons test.
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